Specialty Pharmacy

The FDA approved Elelyso (taliglucerase alfa), the first drug ever produced in a genetically engineered plant cell.

Women with autoimmune disorders such as RA generally have fewer children than they would like to have, according to a survey that appeared recently in Arthritis Care and Research.

Novartis Pharmaceuticals Corporation announced that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

The United States Food and Drug Administration approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

The specialty drug trend is projected to rise 17.1% in 2012, 19% in 2013, and 22% in 2014.

URAC developed a specialty pharmacy accreditation program because it is one of the key distribution channels for pharmacy benefit management, and it extends URAC's consumer protection and empowerment efforts in managed care pharmacy.

Managed Health Care Associates, Inc (MHA), announced the launch of MHA Clinical Therapy Management (CTM), a proprietary application used to assist pharmacies in the clinical management of patients utilizing specialty therapies.

Presenters from the Academy of Managed Care Pharmacy (AMCP) 24th Annual Meeting recently discussed the newest updates in specialty pharmacy.

Express Scripts recently announced that their new Drug Trend Report is available for download.

Diplomat Specialty Pharmacy, the nation's largest, privately owned specialty pharmacy, announced today that Gary Rice, RPh, a veteran specialty pharmacy executive, has joined Diplomat's executive team as vice president of clinical services.

AnaptysBio, Inc, a privately held therapeutic antibody company, recently announced a strategic partnership with Celgene Corporation to develop novel antibodies against multiple therapeutic targets.

New combination pills set to hit the market are expected to be more expensive than prior treatments.

FDA lab tests have confirmed that a counterfeit version of Roche's Altuzan 400mg/16ml (bevacizumab), an injectable cancer medication, found in the United States contains no active ingredient.

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1000 human cancer cell lines used in drug research and development.

The FTC's approval of the highly publicized merger may depend on the divestiture of some of Medco's assets.

The FDA today approved Omontys (peginesatide) to treat anemia, a condition in which the body does not have enough healthy red blood cells, in adult dialysis patients who have chronic kidney disease (CKD).

ARIAD Pharmaceuticals, Inc today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.

Cost-sharing practices that limit access to vital medications for West Virginians with serious health conditions may soon be alleviated thanks to a bill just introduced in Congress. The bi-partisan legislation, supported by the American College of Rheumatology, the Arthritis Foundation, and other medical and patient groups, has been introduced by Rep David B. McKinley (R,WV) and Rep Lois Capps (D,CA).

GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the FDA voted 11 to 2 that evidence from clinical studies support a favorable benefit–risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy.

A new letter goes out to the FTC requesting that their Express Scripts-Medco review include a careful assessment of specialty pharmacy and exclusive distribution contracts.

Randell "RJ" Correia, PharmD, Senior Vice President, Pharmacy Services, Optum Rx, addresses the rapid rise of specialty pharmacy spending. Dr. Correia discusses the possible complications health reform exchanges may cause and the impact they will have on the future of pharmacy benefit drug management.

New research from Medco Health Solutions Inc shows that many patients using oral cancer medications are also on other drugs that could reduce the effectiveness of the cancer treatment or increase its toxicity.

AmerisourceBergen acquires World Courier Group, Inc, and expands its international market reach for specialty medications.

69% of the employer groups studied in this report want more education on specialty pharmacy services.

Managed Health Care Associates, Inc. (MHA), a leading health care service company focused on alternate site health care providers, announced the completion of its fifth annual Independent Long Term Care Member Study, the results of which were released at the 2012 MHA Business Summit, March 2, 2012 in Las Vegas, Nevada.

The Infectious Diseases Society of America (IDSA) proposed a new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.

Prime Therapeutics and EMD Serono entered into an agreement where patient adherence and health outcomes data determine whether or not rebates are given for a drug.

Two companies focused on delivering preventative care to individuals looking to fight chronic disease with nutrition, fitness, and bioidentical hormone therapy-Diplomat Specialty Pharmacy and Ageology-announced that they have formed a strategic alliance.